Amneal Pharmaceuticals, Inc.

NASDAQ:AMRX

Drug Manufacturers - Specialty & Generic

Healthcare
$21.88 -0.90%

-$0.15 today

Market cap
$7.62B
Beta
1.32
P/E (TTM)
43.4
EPS (TTM)
$0.37
52W Low $7.67High $16.61

Volume 1.91M

Average 1.75M

AMRX Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Amneal Pharmaceuticals, Inc.NASDAQ: AMRX

Revenue · Q2 FY2026 · quarter ended Jun 2026

Revenue grows in line with its trailing trend

Q2 FY2026 revenue of $796.2M rose 9.9% year over year, ahead of the +9.3% change in trailing-twelve-month revenue. Sequentially, it rose 10.2% from the prior quarter. Over 3 fiscal years it compounded at +10.9% a year.

Context

  • Revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 5 analysts of $3.21B (+6.4%) for the fiscal year ending Dec 2026, a slowdown from the +8.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$796.2M+10.2% QoQ
Last fiscal yearDec 2025
$3.02B+8.0% YoY
LTMJun 2026
$3.12B+9.3% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+9.9%+4.2%-5.7 pp
1 year+8.0%+6.4%-1.7 pp
3-year CAGR+10.9%+8.7%-2.2 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
3.02B USD
Year-over-year change
+8.0%
4-year CAGR
+9.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How AMRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +9.3% is the 4th highest of 11, against a peer median of +3.1%.
  • Over three fiscal years its annual growth of +10.9% compares with a peer median of +6.5%.
AMRX Competitors
Revenue for AMRX and competitors
Company Period LTM YoY 3-year CAGR
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹331.38B INR-3.1%+12.9%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$17.31B USD+4.1%+5.0%
VTRSViatris Inc.LTM Jun 2026$14.74B USD+4.4%-4.2%
BHCBausch Health Companies Inc.LTM Jun 2026$10.85B USD+10.1%+8.1%
PRGOPerrigo Company plcLTM Jun 2026$4.14B USD-4.2%-1.5%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$3.12B USD+9.3%+10.9%
INDVIndivior Pharmaceuticals IncLTM Jun 2026$1.33B USD+13.5%+11.2%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$923.71M USD+37.0%+40.8%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$720.53M USD-1.1%+13.0%
EBSEmergent BioSolutions Inc.LTM Mar 2026$676.8M USD-29.9%-12.7%
CPIXCumberland Pharmaceuticals Inc.LTM Mar 2026$41.94M USD+2.1%+2.0%
Peer median (excluding AMRX) —+3.1%+6.5%

Competitors are the stored peer set for AMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.09B2.21B2.39B2.79B3.02B
Cost of Revenue1.32B1.42B1.53B1.77B1.88B
Gross Profit768.97M791.46M863.87M1.02B1.14B
Gross Margin36.7%35.8%36.1%36.5%37.6%
Research & Development209.56M208.66M194.75M190.71M186.18M
Selling, General & Admin365.5M399.7M429.68M476.44M526.83M
Operating Expenses616.26M886.39M659.5M771.11M713M
Depreciation & Amortization233.41M240.18M229.4M236.19M223.57M
EBITDA401.1M440.21M500.78M439.77M603.87M
EBITDA Margin19.2%19.9%20.9%15.7%20.0%
Operating Income152.72M(94.93M)204.37M249.33M423.09M
Operating Margin7.3%-4.3%8.5%8.9%14.0%
Interest Income00000
Interest Expense136.33M158.38M210.63M258.6M241.09M
Other Income / Expenses(121.35M)(153.2M)(244.64M)(304.34M)(283.88M)
Income Before Tax31.37M(248.13M)(40.27M)(55.01M)139.21M
Pre-Tax Margin1.5%-11.2%-1.7%-2.0%4.6%
Income Tax Expense11.2M6.66M8.45M18.86M11.28M
Net Income10.62M(129.99M)(83.99M)(116.89M)72.06M
Net Margin0.5%-5.9%-3.5%-4.2%2.4%
EPS (Basic)0.07(0.86)(0.48)(0.38)0.23
EPS (Diluted)0.07(0.86)(0.48)(0.38)0.22
Weighted Avg Shares148.92M150.94M174.99M308.98M313.37M
Weighted Avg Shares (Diluted)151.82M150.94M176.14M308.98M324.81M

Amneal Pharmaceuticals, Inc.

NASDAQ:AMRX

Intrinsic Alpha fair value

Locked

Current Price

$21.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.